Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel versus placebo in non-functioning entero-pancreatic neuroendocrine tumors
2005-004904-35Phase 3Completed
- Sponsor
- Ipsen
- Start
- Feb 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Pancreatic neuroendocrine tumor (pNET) and non-functioning pancreatic neuroendocrine tumor (NF-pNET) comparing Lanreotide Autogel with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Feb 2006; status: completed.
02
Drugs
lanreotide
03
Conditions
Pancreatic neuroendocrine tumor (pNET)non-functioning pancreatic neuroendocrine tumor (NF-pNET)
Beyond the preview
Go deeper on 2005-004904-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004904-35.